Acrivon Therapeutics Management
Management criteria checks 3/4
Acrivon Therapeutics' CEO is Peter Blume-Jensen, appointed in Mar 2018, has a tenure of 7.17 years. total yearly compensation is $2.00M, comprised of 32.8% salary and 67.2% bonuses, including company stock and options. directly owns 5.27% of the company’s shares, worth $1.82M. The average tenure of the management team and the board of directors is 3.1 years and 3.4 years respectively.
Key information
Peter Blume-Jensen
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 32.75% |
| CEO tenure | 7.2yrs |
| CEO ownership | 5.3% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Mar 27
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Dec 12We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$84m |
| Dec 31 2024 | US$2m | US$655k | -US$81m |
| Sep 30 2024 | n/a | n/a | -US$77m |
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$64m |
| Dec 31 2023 | US$6m | US$629k | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$22m | US$536k | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$757k | US$430k | -US$16m |
Compensation vs Market: Peter's total compensation ($USD2.00M) is above average for companies of similar size in the US market ($USD659.32K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Blume-Jensen (61 yo)
7.2yrs
Tenure
US$2,000,312
Compensation
Mr. Peter Blume-Jensen, MD, PhD., is Member of Advisory Board of Bio-AI Health Inc. He served as a Member of Advisory Board at Kernal Biologics, Inc. until February 2025. Mr. Blume-Jensen is the Founder, C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.2yrs | US$2.00m | 5.27% $ 1.8m | |
| Co-Founder | no data | US$1.20m | 0.97% $ 333.9k | |
| Chief Operating Officer | 2.8yrs | US$1.15m | 0.17% $ 57.8k | |
| CFO & Principal Financial Officer | less than a year | no data | 0.0078% $ 2.7k | |
| Vice President of Finance & Accounting | no data | no data | 0.014% $ 4.9k | |
| Vice President of Quality & Compliance | 3.1yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2.6yrs | US$697.00k | 0.057% $ 19.6k | |
| Chief Development Officer | 4.2yrs | US$538.08k | 0.025% $ 8.5k | |
| Academic Co-Founder | no data | no data | no data | |
| VP & Head of Data Science | 3.1yrs | no data | no data | |
| Head of Clinical CDx Operations | 3.1yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | no data | no data | no data |
3.1yrs
Average Tenure
54yo
Average Age
Experienced Management: ACRV's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.2yrs | US$2.00m | 5.27% $ 1.8m | |
| Co-Founder | 7.2yrs | US$1.20m | 0.97% $ 333.9k | |
| Academic Co-Founder | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Independent Director | 1.3yrs | US$122.48k | 0.046% $ 15.9k | |
| Independent Director | 4.6yrs | US$58.13k | 0.16% $ 56.8k | |
| Independent Director | 2.6yrs | US$151.04k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$152.29k | 0.13% $ 45.1k | |
| Independent Director | 1.2yrs | US$188.33k | 0.043% $ 14.9k | |
| Independent Director | 3.5yrs | US$151.04k | 0.16% $ 56.8k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Advisory Board | 3.4yrs | no data | no data |
3.4yrs
Average Tenure
55.5yo
Average Age
Experienced Board: ACRV's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 10:52 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acrivon Therapeutics, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |